# US Sacroiliitis Treatment Market > US Sacroiliitis Treatment Market Research Report By Type (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation) and By End-user (Hospitals, Clinics, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 2.02% - **2024:** $ 9.68 Billion - **2025:** $ 9.88 Billion - **2035:** $ 12.06 Billion - **Key Players:** AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) **Report ID:** MRFR/HC/52347-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-sacroiliitis-treatment-market-54110 --- ## Market Summary ## **US Sacroiliitis Treatment Market Overview** As per MRFR analysis, the US Sacroiliitis Treatment Market Size was estimated at 8.18 (USD Billion) in 2023. The US Sacroiliitis Treatment Market is expected to grow from 10.5 (USD Billion) in 2024 to 65 (USD Billion) by 2035. The US Sacroiliitis Treatment Market CAGR (growth rate) is expected to be around 18.025% during the forecast period (2025 - 2035) **Key US Sacroiliitis Treatment Market Trends Highlighted** The growing number of people seeking medical attention for inflammatory illnesses and chronic pain is driving a noteworthy increase in the diagnosis and awareness of sacroiliitis in the United States. Better access to healthcare and modifications to recommendations that support prompt and precise diagnosis have an impact on this development. Patients are more likely to receive the right treatment options sooner if more medical professionals and specialists are aware of the subtleties of sacroiliitis. The development of therapeutic alternatives, such as biologics and targeted treatments, which have proven successful in treating inflammatory diseases, is another important motivator. Both patients and medical professionals are being encouraged to investigate more aggressive treatment approaches by these advancements. The growth of telemedicine, which enables medical professionals to access patients in remote locations or those with mobility issues, is creating new opportunities in the US market. In addition to making treatment more accessible, this guarantees continued care and observation of sacroiliitis patients. The aging of the US population is also contributing to an increase in the incidence of sacroiliac joint disorders such arthritis. The potential for creating individualized treatment regimens is increasing as more people look for specialized healthcare solutions. More ongoing research has been conducted recently to better understand the underlying causes of sacroiliitis and develop more specialized and efficient treatments. Technology is increasingly being incorporated into treatment approaches, such as through the use of smartphone apps for patient education and symptom monitoring. All things considered, the US sacroiliitis treatment market is growing quickly due to improvements in medicine, heightened patient involvement, and an emphasis on individualized therapy. For medical professionals and pharmaceutical businesses focusing on the treatment of sacroiliitis, this setting offers a bright future. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **US Sacroiliitis Treatment Market Drivers** **Rising Prevalence of Sacroiliitis Among the US Population** The US Sacroiliitis Treatment Market is witnessing significant growth due to the increasing prevalence of sacroiliitis among the population. According to the Centers for Disease Control and Prevention (CDC), inflammatory diseases such as rheumatoid arthritis and ankylosing spondylitis, which are closely linked to sacroiliitis, have shown a rising trend, with approximately 1.5 million adults diagnosed with rheumatoid arthritis in the US. This increase drives demand for effective treatment options and influences healthcare expenditures on sacroiliitis management, estimated to grow substantially in the coming years. The need for targeted therapies to alleviate symptoms and improve quality of life is attracting significant interest from established organizations like AbbVie and Celgene, which are advancing research into innovative treatments that directly address this rising patient base. With national initiatives aimed at enhancing awareness of musculoskeletal disorders, further patient demographic shifts are anticipated, thereby fostering the growth of the US [Sacroiliitis Treatment Market](../../../reports/sacroiliitis-treatment-market-6590). **Advancements in Treatment Technologies** Continuous advancements in treatment technologies are significantly impacting the growth of the US Sacroiliitis Treatment Market. The development of biologic agents and targeted therapies has revolutionized treatment options, allowing for more effective management of sacroiliitis. For instance, drugs such as Tumor Necrosis Factor (TNF) inhibitors have marked a turning point in treatment effectiveness, as highlighted by recent studies showing over 50% of patients experience improvement in symptoms. Established organizations like Amgen and Johnson & Johnson are at the forefront of developing these advanced therapies, ensuring accessibility for patients. The rise in innovation is driven by Research and Development investments aimed at understanding the pathophysiology of sacroiliitis, translating to improved therapeutic outcomes and a growing market presence. **Increasing Focus on Chronic Pain Management** The US Sacroiliitis Treatment Market is benefiting from a heightened focus on chronic pain management strategies across the healthcare sector. With chronic pain affecting approximately 20% of adults in the US, as reported by the National Institute of Health (NIH), there is a pressing need for effective interventions for conditions like sacroiliitis. Healthcare policies and initiatives are increasingly emphasizing the importance of addressing chronic pain, which in turn is driving investment in comprehensive treatment modalities including physical therapy and pharmacological options. Leading organizations, such as the American Pain Society, are advocating for improved pain management solutions, influencing guidelines to incorporate more robust strategies that encompass the management of sacroiliitis. This growing awareness and policy support are expected to create a conducive environment for the expansion of the US Sacroiliitis Treatment Market. **US Sacroiliitis Treatment Market Segment Insights** **Sacroiliitis Treatment Market Type Insights** The US Sacroiliitis Treatment Market depicts a robust structure categorized into various types, each catering to distinct therapeutic needs. The main types include Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, and Electrical Stimulation. Medications play a vital role in the initial management of sacroiliitis, commonly involving nonsteroidal anti-inflammatory drugs (NSAIDs), which alleviate pain and reduce inflammation. This segment has garnered attention due to its easy accessibility and widespread physician preference in outpatient settings. In contrast, Joint Injections, often involving corticosteroids, offer targeted relief for patients whose symptoms do not respond adequately to oral medications, contributing significantly to pain management strategies. Moreover, Joint Fusion procedures are critical for patients with chronic sacroiliitis, as they provide a long-term solution by stabilizing the joint, thereby improving overall function for individuals suffering from significant impairment. Radiofrequency Denervation has emerged as a minimally invasive option that diminishes pain signals from the affected nerve, contributing to enhanced patient quality of life through sustained pain management. Lastly, Electrical Stimulation techniques provide an alternative approach by utilizing electrical impulses to disrupt pain signals, which is gaining traction as patients seek out less invasive therapies. The increasing prevalence of sacroiliitis in the US population, coupled with the rise in healthcare awareness and improved diagnostic capabilities, is propelling the demand for varied treatment types. The ongoing research in efficacy and safety profiles of these therapies is anticipated to shape the market's evolution. Furthermore, advancements in technology and treatment methodologies are enhancing the clinical outcomes in various types of sacroiliitis treatments, thus ensuring that patients have adequate options tailored to their specific needs. As healthcare providers continue to seek effective management protocols, these types will likely remain foundational in the overall landscape of the US Sacroiliitis Treatment Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Sacroiliitis Treatment Market End-user Insights** The US Sacroiliitis Treatment Market's End-user segment encompasses a diverse range of facilities, primarily focusing on Hospitals and Clinics, alongside Other healthcare settings. Hospitals play an essential role in providing advanced diagnostic and treatment options due to their access to specialized equipment and multidisciplinary teams, making them a significant contributor to the overall care of patients suffering from sacroiliitis. Clinics offer more accessible and individualized treatment approaches, which are favored by many patients in managing their conditions effectively. Additionally, Other facilities, including outpatient care centers, are increasingly important as they provide alternative care settings, enhancing patient convenience and reducing the burden on traditional hospitals. As the prevalence of sacroiliitis continues to grow, driven partly by rising awareness and better diagnostic techniques, the importance of these End-users will become more pronounced. The changing dynamics of healthcare, including the shift towards outpatient services, present numerous opportunities for these facilities to expand their offerings and improve patient outcomes in the US Sacroiliitis Treatment Market. Moreover, advancements in treatment modalities are likely to influence the operational strategies of hospitals and clinics, further shaping their roles in the market landscape. **US Sacroiliitis Treatment Market Key Players and Competitive Insights** The US Sacroiliitis Treatment Market is characterized by a diverse array of treatment options designed to address the complexities associated with sacroiliitis, an inflammatory condition that affects the sacroiliac joints. This market is informed by ongoing research and development initiatives aimed at improving therapeutic efficacy and patient outcomes. The competitive landscape is shaped by key players that strive to innovate while navigating regulatory environments, patent challenges, and the ever-changing dynamics of healthcare needs. With the increasing incidence of autoimmune disorders and the growing recognition of sacroiliitis as a significant contributor to chronic pain, the demand for effective treatments is on the rise, thereby intensifying competition among market participants. Players in this market are becoming more tactical in their approaches, seeking partnerships and strategic alliances to enhance their product portfolios, penetrate new market segments, and ultimately improve patient access to treatments. Amgen stands out in the US Sacroiliitis Treatment Market due to its robust pipeline and expertise in biotechnology which allows for the development of targeted therapies. Their strengths include a strong presence in the immunology sector, particularly with therapies focusing on inflammatory conditions, positioning them uniquely to address the needs of sacroiliitis patients. Amgen’s established credibility is bolstered by extensive clinical trials that underscore the safety and efficacy of their products, fostering trust among healthcare providers and patients alike. Beyond its existing therapies, the company is known for its commitment to research and continuous innovation. Their proactive approach in collaborating with research institutions and other biopharmaceutical companies rounds out a comprehensive strategy aimed at expanding their footprint in the US market. Bristol-Myers Squibb is another significant player in the US Sacroiliitis Treatment Market, recognized for its strong portfolio of immuno-oncology products that also have implications for inflammatory diseases. The company capitalizes on its established reputation and extensive research capabilities, focusing on both small molecules and biologics to address unmet medical needs in sacroiliitis. Core products in this therapeutic area contribute to a solid market presence, while strategic mergers and acquisitions have bolstered their research infrastructure and accelerated the development of new therapies. Bristol-Myers Squibb has made notable investments in clinical programs specifically targeting sacroiliitis, ensuring that they remain at the forefront of treatment advancements. Their commitment to comprehensive patient care, coupled with a focus on innovative solutions, positions them effectively within this competitive landscape, allowing for ongoing engagement with healthcare professionals through educational initiatives and support programs that enhance treatment uptake and patient adherence. **Key Companies in the US Sacroiliitis Treatment Market Include** - Amgen - Bristol-Myers Squibb - Pfizer - Regeneron Pharmaceuticals - Roche - Gilead Sciences - Johnson & Johnson - Eli Lilly - AstraZeneca - Merck & Co - Sanofi - Novartis - AbbVie - UCB **US Sacroiliitis Treatment Market Developments** The US Sacroiliitis Treatment Market has seen significant developments recently. In August 2023, Regeneron Pharmaceuticals announced positive results from a clinical trial for its innovative treatment aimed at alleviating symptoms associated with sacroiliitis, indicating potential shifts in treatment protocols. Meanwhile, Amgen and Bristol Myers Squibb continue to expand their Research and Development efforts in biologic therapies for inflammatory diseases, with recent collaborations aimed at enhancing treatment efficacy. Growth in the market valuation is influenced by increasing incidence rates of sacroiliitis, prompting companies like Pfizer and Eli Lilly to innovate rapidly. Additionally, Johnson and Johnson made headlines in October 2022 by launching a new treatment option, which has been well received by both patients and healthcare providers. Notably, Gilead Sciences announced the acquisition of a biopharmaceutical company focused on autoimmune disorders in September 2023, which may enhance its portfolio in the sacroiliitis domain. These developments reflect a heightened focus on the US market and underscore the competitive landscape of pharmaceutical companies including Roche, AstraZeneca, Merck and Co, Sanofi, Novartis, AbbVie, and UCB adapting their strategies to meet growing demands. **Sacroiliitis Treatment Market Segmentation Insights** **Sacroiliitis Treatment Market Type Outlook** - Medications - Joint Injections - Joint Fusion - Radiofrequency Denervation - Electrical Stimulation **Sacroiliitis Treatment Market End-user Outlook** - Hospitals - Clinics - Others ## Market Drivers ### Increased Awareness and Advocacy There appears to be a growing awareness and advocacy surrounding sacroiliitis and related conditions, which may positively impact the treatment market. Patient advocacy groups and healthcare organizations are actively promoting education about sacroiliitis, its symptoms, and available treatment options. This heightened awareness is likely to lead to increased patient engagement and demand for medical consultations. Furthermore, educational campaigns may encourage individuals to seek early intervention, which could result in a larger patient base for the sacroiliitis treatment market. As awareness continues to rise, it is anticipated that more patients will pursue effective treatment solutions, thereby driving market growth. ### Advancements in Diagnostic Technologies Technological innovations in diagnostic imaging and assessment tools are likely to enhance the identification of sacroiliitis, thereby driving the treatment market. Enhanced imaging techniques, such as MRI and CT scans, allow for more accurate detection of sacroiliac joint inflammation. This improved diagnostic capability may lead to increased referrals to specialists and subsequent treatment interventions. The market for diagnostic imaging in the US is projected to grow at a CAGR of around 5.5% through 2026, indicating a robust demand for advanced diagnostic solutions. As healthcare providers become more adept at diagnosing sacroiliitis, the treatment market is expected to expand, with a greater emphasis on tailored therapeutic approaches. ### Rising Prevalence of Autoimmune Disorders The increasing incidence of autoimmune disorders, particularly ankylosing spondylitis and other related conditions, appears to be a significant driver for the sacroiliitis treatment market. As these disorders often lead to sacroiliitis, the demand for effective treatment options is likely to rise. Recent estimates suggest that autoimmune diseases affect approximately 24 million individuals in the US, with a notable portion experiencing sacroiliitis. This growing patient population necessitates advancements in treatment modalities, including pharmaceuticals and physical therapies, thereby propelling the market forward. Furthermore, the rising awareness of these conditions among healthcare providers and patients may lead to earlier diagnosis and intervention, further stimulating the sacroiliitis treatment market. ### Growing Investment in Research and Development The sacroiliitis treatment market is likely to benefit from increased investment in research and development (R&D) by pharmaceutical companies and academic institutions. This investment is aimed at discovering novel therapeutic agents and treatment protocols that can effectively manage sacroiliitis. In recent years, funding for R&D in the field of rheumatology has seen a notable uptick, with expenditures reaching approximately $5 billion annually in the US. This financial commitment suggests a strong focus on developing innovative treatments, which may include biologics and targeted therapies. As new treatment options emerge, the sacroiliitis treatment market is expected to experience growth driven by enhanced efficacy and safety profiles. ### Aging Population and Increased Healthcare Access The aging population in the US is a critical factor influencing the sacroiliitis treatment market. As individuals age, the likelihood of developing musculoskeletal disorders, including sacroiliitis, increases. The US Census Bureau projects that by 2030, approximately 20% of the population will be 65 years or older, which may lead to a higher prevalence of sacroiliitis. Additionally, improved access to healthcare services, including insurance coverage and availability of specialists, is likely to facilitate timely diagnosis and treatment. This demographic shift, combined with enhanced healthcare access, suggests a growing market for sacroiliitis treatments, as older adults seek effective management options for their conditions. ## Future Outlook The [Sacroiliitis Treatment Market](https://www.marketresearchfuture.com/reports/sacroiliitis-treatment-market-6590) is projected to grow at a 2.02% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in biologics and targeted therapies - Expansion of patient education programs to enhance treatment adherence By 2035, the market is expected to achieve a robust position, reflecting steady growth and innovation. ## Segment Insights ### By Type: Medications (Largest) vs. Joint Injections (Fastest-Growing) In the US sacroiliitis treatment market, Medications represent the largest share, driven by a wide array of pharmaceutical options available for pain management. Joint Injections also hold a significant portion of the market but are rapidly gaining traction as a preferred treatment option, especially among patients seeking immediate relief and reduced inflammation. These two categories, while distinct, play complementary roles in the overall treatment landscape. Analysis indicates that the growth trend in the Joint Injections segment is heavily influenced by advances in injection techniques and an increasing shift towards less invasive procedures. Patients and healthcare providers are favoring injections for their targeted delivery of relief, which enhances their effectiveness and leads to quicker recovery times. Meanwhile, Medications remain essential, particularly as new drugs enter the market, catering to diverse patient needs. Medications (Dominant) vs. Joint Injections (Emerging) Medications dominate the treatment options for sacroiliitis, offering a variety of NSAIDs, corticosteroids, and other adjunctive therapies that cater to different severity levels of the condition. This dominance stems from established efficacy, widespread availability, and familiarity among healthcare practitioners. On the other hand, Joint Injections are emerging as a compelling alternative, especially for patients who do not respond well to oral medications. These injections provide a targeted approach, delivering pain relief directly to the affected area, thereby enhancing patient outcomes. The shift towards these injections is driven by their ability to minimize systemic side effects while providing effective management of inflammation and pain. ### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the US sacroiliitis treatment market, hospitals hold the largest share among end-users, driven by their capacity to offer comprehensive treatment plans and specialized care. Clinics also play a significant role, catering to patients seeking outpatient services, thus contributing to a diverse treatment landscape. The competition between hospitals and clinics shapes the market dynamics and influences patient preferences for treatment options. Growth trends indicate a rising demand for sacroiliitis treatments in clinics, attributed to the increasing number of patients seeking convenient healthcare solutions. This shift reflects a broader trend towards outpatient care, where clinics capitalize on providing faster access and reduced waiting times. Hospitals are adapting by integrating specialized services for chronic conditions, contributing to sustained growth across both segments. Hospitals (Dominant) vs. Clinics (Emerging) Hospitals stand out as the dominant players in the US sacroiliitis treatment market, characterized by their extensive resources and multidisciplinary teams that can address complex cases. They are equipped to perform advanced diagnostic and therapeutic procedures, thus attracting a significant patient base. In contrast, clinics are emerging as a preferred choice for many patients, offering personalized care and shorter wait times. This trend is fostering innovation within clinics, where there is an increasing focus on minimally invasive techniques and patient education, effectively enhancing the overall treatment experience. ## Competitive Benchmarking The sacroiliitis treatment market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie Inc (US), Amgen Inc (US), and Johnson & Johnson (US) are actively engaged in enhancing their product offerings and expanding their market presence. AbbVie Inc (US) has positioned itself as a leader in immunology, focusing on the development of novel therapies that target the underlying mechanisms of sacroiliitis. Meanwhile, Amgen Inc (US) emphasizes its commitment to biologics and biosimilars, aiming to leverage its expertise in these areas to capture a larger share of the market. Johnson & Johnson (US) continues to invest in research and development, particularly in the realm of digital health solutions, which may enhance treatment adherence and patient outcomes. Collectively, these strategies contribute to a dynamic competitive environment where innovation and patient engagement are paramount.The business tactics employed by these companies reflect a nuanced understanding of the market's structure, which appears to be moderately fragmented. Localizing manufacturing and optimizing supply chains are critical strategies that enhance operational efficiency and reduce costs. The influence of key players is significant, as their combined efforts in research, development, and marketing shape the overall market dynamics. This competitive structure allows for both established companies and emerging players to coexist, fostering an environment ripe for innovation and growth. In October AbbVie Inc (US) announced a strategic partnership with a leading digital health company to develop a mobile application aimed at improving patient engagement in sacroiliitis treatment. This initiative is expected to enhance patient adherence to prescribed therapies and provide valuable data for ongoing clinical research. The strategic importance of this partnership lies in its potential to bridge the gap between traditional treatment methods and modern digital solutions, thereby improving overall patient outcomes. In September Amgen Inc (US) launched a new biosimilar product specifically targeting the treatment of sacroiliitis, which is anticipated to increase access to effective therapies for patients. This move not only reinforces Amgen's commitment to affordability but also positions the company as a key player in the biosimilars market. The introduction of this product is likely to stimulate competition and drive down costs, benefiting patients and healthcare providers alike. In August Johnson & Johnson (US) expanded its clinical trial program for a novel therapy aimed at treating sacroiliitis, focusing on diverse patient populations. This expansion underscores the company's dedication to inclusivity in clinical research and its commitment to developing therapies that address the needs of various demographic groups. The strategic importance of this initiative lies in its potential to yield more comprehensive data, ultimately leading to more effective treatment options. As of November the competitive trends in the sacroiliitis treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient care. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift may redefine how companies approach market entry and product development, emphasizing the importance of adaptability and forward-thinking strategies. ## Recent News & Developments The US Sacroiliitis Treatment Market has seen significant developments recently. In August 2023, Regeneron Pharmaceuticals announced positive results from a clinical trial for its innovative treatment aimed at alleviating symptoms associated with sacroiliitis, indicating potential shifts in treatment protocols. Meanwhile, Amgen and Bristol Myers Squibb continue to expand their Research and Development efforts in biologic therapies for inflammatory diseases, with recent collaborations aimed at enhancing treatment efficacy. Growth in the market valuation is influenced by increasing incidence rates of sacroiliitis, prompting companies like Pfizer and Eli Lilly to innovate rapidly. Additionally, Johnson and Johnson made headlines in October 2022 by launching a new treatment option, which has been well received by both patients and healthcare providers. Notably, Gilead Sciences announced the acquisition of a biopharmaceutical company focused on autoimmune disorders in September 2023, which may enhance its portfolio in the sacroiliitis domain. These developments reflect a heightened focus on the US market and underscore the competitive landscape of pharmaceutical companies including Roche, AstraZeneca, Merck and Co, Sanofi, Novartis, AbbVie, and UCB adapting their strategies to meet growing demands. ## Report Scope | MARKET SIZE 2024 | 9.68(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 9.88(USD Billion) | | MARKET SIZE 2035 | 12.06(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.02% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) | | Segments Covered | Type, End-User | | Key Market Opportunities | Emerging biologics and personalized therapies enhance treatment options in the sacroiliitis treatment market. | | Key Market Dynamics | Rising demand for biologics and personalized therapies drives innovation in the sacroiliitis treatment market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US sacroiliitis treatment market in 2024?** A: The market valuation of the US sacroiliitis treatment market was $9.68 Billion in 2024. **Q: What is the projected market valuation for the US sacroiliitis treatment market by 2035?** A: The projected market valuation for the US sacroiliitis treatment market is $12.06 Billion by 2035. **Q: What is the expected CAGR for the US sacroiliitis treatment market during the forecast period 2025 - 2035?** A: The expected CAGR for the US sacroiliitis treatment market during the forecast period 2025 - 2035 is 2.02%. **Q: Which segment had the highest valuation in the US sacroiliitis treatment market in 2024?** A: In 2024, the Medications segment had the highest valuation at $3.84 Billion. **Q: What is the projected valuation for the Joint Injections segment by 2035?** A: The projected valuation for the Joint Injections segment is $3.12 Billion by 2035. **Q: Which end-user segment is expected to grow the most by 2035?** A: The Hospitals segment is expected to grow the most, with a projected valuation of $4.68 Billion by 2035. **Q: Who are the key players in the US sacroiliitis treatment market?** A: Key players in the US sacroiliitis treatment market include AbbVie Inc, Amgen Inc, and Johnson & Johnson. **Q: What was the valuation of the Electrical Stimulation segment in 2024?** A: The valuation of the Electrical Stimulation segment was $0.56 Billion in 2024. **Q: How does the Joint Fusion segment's valuation compare between 2024 and 2035?** A: The Joint Fusion segment's valuation increased from $1.44 Billion in 2024 to a projected $1.76 Billion by 2035. **Q: What is the expected growth trend for the Clinics end-user segment by 2035?** A: The Clinics end-user segment is expected to grow from $2.88 Billion in 2024 to $3.48 Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-sacroiliitis-treatment-market-54110*